Insulin pump therapy plus glucose sensing for continuous glocose monitoring in children with type 1 diabetes: What will come next? [Terapia con microinfusore e sensore della glicemia in continuo nei bambini con diabete di tipo 1… guardando al futuro!]
Scaramuzza A.,University of Milan |
Bonfanti R.,Diabetes Research Institute OSR DRI |
Schiaffini R.,UOC Endocrinologia e Diabetologia Pediatrica
Giornale Italiano di Diabetologia e Metabolismo | Year: 2014
The first instrument that measured blood sugar “continuously” appeared 15 years ago. Since then, subcutaneous glycemic sensors have made it possible to obtain continuous blood glucose measurements, giving physicians or patients real-time pictures of the levels of sugar in the blood. The quality of the technology has substantially improved – in the measurement and interpretation of results – although much remains to be done, especially as regards the sensors’ accuracy and reliability. Some very important studies (RealTrend, Eurythmics, ONSET, SWITCH, STAR 3, INTERPRET) have confirmed that continuous glucose monitoring contributes added value to insulin therapy, especially when an insulin pump is used, to achieve therapeutic goals. For almost ten years now it has been possible to combine the pump with a blood glucose sensor, giving what is known as sensor-augmented insulin pump therapy. In the last two years, the findings from other studies have been published, with important updates on blood glucose monitoring implemented with automatic suspension of the insulin infusion as soon as a predetermined threshold is achieved (ASPIRE) or even in relation to the expectation that the threshold will soon be reached (PILGRIM). © 2014, UTET Periodici Scientifici srl. All rights reserved.
Analysis of a cohort of pediatric patients treated with continuous subcutaneous insulin infusion [Analisi di una coorte di pazienti in età pediatrica in terapia con microinfusore continuo di insulina sottocute]
Rubino C.,Diabetes Research Institute OSR DRI |
Rigamonti A.,Diabetes Research Institute OSR DRI |
Frontino G.,Diabetes Research Institute OSR DRI |
Battaglino R.,Diabetes Research Institute OSR DRI |
And 5 more authors.
Giornale Italiano di Diabetologia e Metabolismo | Year: 2015
We analyzed a cohort of pediatric patients with type 1 diabetes mellitus treated with continuous insulin infusion (CSII), followed at the San Raffaele Hospital (Milan, Italy) in the period 2007-2014. We collected data from a questionnaire and from outpatient charts for 206 patients, whose average age was 12.93 years; 93.2% followed our protocol for starting CSII. The drop-out rate was 3.4%. Mean HbA1c was comparable to that of patients on multiple daily injections (MDI) and long-term analysis did not show any significant changes before and after CSII. The incidence of acute complications was low: 1.42 episodes/100 patients/year for severe hypoglycemia (about 50% fewer than in those using MDI), 1.11 episodes/100 patients/year for diabetic ketoacidosis. CSII patients did not gain weight and we found a significant relation between follow-up BMI and HbA1c. There was also a correlation between the use of a vertical cannula and HbA1c reduction. Most of these patients used advanced functions (bolus calculator, temporary basal rates), telemedicine and carbohydrate counting, but only carbohydrate counting was related to the improvement in HbA1c: 60.2% used continuous glucose monitoring (CGM) but here too there was no relation with reduced HbA1c; 53.4% replaced the pump at least once and 41.7% reported malfunctions (no adverse events). The distribution of insulin basal rates differed between age groups 0-6, 7-12, and 13-18 years; this confirms other reports and the advantage of CSII over MDI in children under the age of six. The average number of bolus injections was lower than expected and was not significantly related with HbA1c. CSII is safe and effective. Most studies report no significant improvement in HbA1c, but there is a lower incidence of acute complications. CSII therapy is a mandatory step towards the application of new diabetes technology (artificial pancreas) but further studies need to assess long-term cost and benefits. © 2015 UTET Periodici Scientifici srl. All rights reserved.